Marksans Pharma
₹317
- Market Cap
- ₹14,077Cr.
- P/E Ratio
- 27.2
- P/B Ratio
- 4.75
- EPS (TTM)
- ₹11.65
- Div Yield
- 0.28%
- ROCE
- 18.8%
- ROE
- 15.2%
52W Low: ₹15552W High: ₹351
At a glance
- Sales have grown 17.0% a year over three years.
- Debt is 0.11× its shareholders’ equity.
From reported financials and exchange prices. Descriptive only, not advice.
Marksans_Pharma — Price
Interval
Style
Failed: 503
Scorecard
Market: risk-off · breadth 377/8Minerviniuptrend checks met
90RS Rankvs all stocks, 1–99
bullRSI Regimemomentum range
16Trend (ADX)trend strength
1/4CAN SLIMprice & volume checks
upSupertrendprice vs trailing line
upVolume Flowbuying vs selling volume
Factual technical classifications from price/volume data — research signals, not investment advice. Hover or tap any badge for what it means.
Evenstocks Score
Middle third
Overall
Valuation
Quality
Fundamental
Growth
Investment Checklist
Quick assessment based on key parametersPerformance
N/ATrailing return unavailableValuation
P/E 27.2P/E: 27.2 | P/B: 4.75Growth
GrowingSales CAGR — 3Y: 17% · 1Y: 20%Profitability
ModerateROCE: 18.8% | ROE: 15.2%Key Metrics
Valuation
PEG Ratio 1.70
Price / Sales 4.44x
Price / FCF 42.8x
Book Value ₹66.7
Margins & returns
Operating Margin 22%
Net Margin 16.4%
Return on Assets 13.5%